BMJ Open · 2016 · 24 citations · 16 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyCircadian RhythmsClinical PharmacologyBlood Pressure ManagementDiabetes ControlDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyAntihypertensive Medication ManagementAntihypertensive TreatmentCardiovascular Autonomic NeuropathyCircadian Blood Pressure VariationCoronary Artery Disease PharmacotherapyDiabetes DurationDouble-blind Trials
OBJECTIVES: Cardiovascular autonomic neuropathy (CAN) and abnormal circadian blood pressure (BP) rhythm are independent cardiovascular risk factors in patients with diabetes and associations between CAN, non-dipping of nocturnal BP and coronary artery disease have been demonstrated. We aimed to test if bedtime dosing (BD) versus morning dosing (MD) of the ACE inhibitor enalapril would affect the 24-hour BP profile in patients with type 1 diabetes (T1D), CAN and non-dipping. SETTING: Secondary healthcare unit in Copenhagen, Denmark. PARTICIPANTS: 24 normoalbuminuric patients with T1D with CAN and non-dipping were included, consisting of mixed gender and Caucasian origin. Mean±SD age, glycosylated haemoglobin and diabetes duration were 60±7 years, 7.9±0.7% (62±7 mmol/mol) and 36±11 years. INTERVENTIONS: In this randomised, placebo-controlled, double-blind cross-over study, the patients were treated for 12 weeks with either MD (20 mg enalapril in the morning and placebo at bedtime) or BD (placebo in the morning and 20 mg enalapril at bedtime), followed by 12 weeks of switched treatment regimen. PRIMARY AND SECONDARY OUTCOME MEASURES: Primary outcome was altered dipping of nocturnal BP. Secondary outcomes included a measurable effect on other cardiovascular risk factors than BP, including left ventricular function (LVF). RESULTS: Systolic BP dipping increased 2.4% (0.03-4.9%; p=0.048) with BD compared to MD of enalapril. There was no increase in mean arterial pressure dipping (2.2% (-0.1% to 4.5%; p=0.07)). No difference was found on measures of LVF (p≥0.15). No adverse events were registered during the study. CONCLUSIONS: We demonstrated that patients with T1D with CAN and non-dipping can be treated with an ACE inhibitor at night as BD as opposed to MD increased BP dipping, thereby diminishing the abnormal BP profile. The potentially beneficial effect on long-term cardiovascular risk remains to be determined. TRIAL REGISTRATION NUMBER: EudraCT2012-002136-90; Post-results.
16
2013 ESH/ESC Guidelines for the management of arterial hypertension
Giuseppe Mancia, Robert Fagard, Krzysztof Narkiewicz et al. · European Heart Journal · 2013 · 13.7K citations · Full text
Standards of Medical Care in Diabetes—2013
Diabetes Care · 2012 · 4.4K citations · Full text
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study
José Boggia, Yan Li, Lutgarde Thijs et al. · The Lancet · 2007 · 873 citations · Full text
Medicine, Cardiology, Nephrology +14
Prognostic Value of the Morning Blood Pressure Surge in 5645 Subjects From 8 Populations
Yan Li, Lutgarde Thijs, Tine W. Hansen et al. · Hypertension · 2010 · 276 citations · Full text